There are currently 36 clinical trials in Virginia Beach, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Urology of Virginia, Urology of Virginia, PLLC, Pfizer Investigational Site and Tidewater Integrated Medical Research. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
An Internet-based Program to Help Cancer Survivors Manage Pain
Recruiting
To determine whether an Internet-based pain coping skills program plus enhanced usual care, compared to enhanced usual care alone, yields significant improvements in the co-primary outcomes of pain severity (as measured by the Brief Pain Inventory (BPI)) and pain interference (also measured by the BPI) from baseline to the post-intervention assessment for cancer survivors with persistent pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Peninsula Cancer Institute - Cancer Specialists of Tidewater, Virginia Beach, Virginia
Conditions: Cancer
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Recruiting
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Peninsula Cancer Institute-Cancer Specialists of Tidewater, Virginia Beach, Virginia
Conditions: Stage III Colon Cancer
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Sentara Neurology Specialists, Virginia Beach, Virginia
Conditions: Focal Onset Seizures
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/28/2025
Locations: Sentara Neurology Specialists, Virginia Beach, Virginia
Conditions: Primary Generalized Tonic-Clonic Seizures
Exactech Shoulder Post Market Clinical Follow-up Study
Recruiting
The objective of this study is to collect and evaluate long-term clinical and radiographic outcomes data in order to better understand the safety and performance of the shoulder arthroplasty over time. This study will follow subjects long-term for a minimum of 10-years, without an early-term restriction on the amount of time they will be followed.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
02/26/2025
Locations: Atlantic Orthopaedics Specialists, Virginia Beach, Virginia
Conditions: Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy, Ankylosing Spondylitis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis, Fracture, Infections
A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancer
Recruiting
The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Urology of Virginia, Virginia Beach, Virginia
Conditions: Prostate Cancer
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Oncology Associates,1950 Glenn Mitchell Drive, Virginia Beach, Virginia
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
CCT-102 or Expectant Management in Delayed Pregnancy Loss
Recruiting
A Phase 3, multi-center clinical trial of a CCT-102 regimen or expectant management to promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss (DPL).
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
02/11/2025
Locations: Tidewater Clinical Research, Virginia Beach, Virginia
Conditions: Early Pregnancy Loss, Delayed Pregnancy Loss
DG1 Spectacle Lens for Myopia Progression Control in Children
Recruiting
The goal of this clinical trial is to evaluate the safety and efficacy of the DG1 spectacle lens for myopia progression control in children. * To assess if the DG1 lens will slow the progression of myopia through an adjusted mean difference (e.g., age and baseline SER) of approximately 0.75D in cycloplegic spherical equivalent autorefraction refractive error compared to single-vision (SV) spectacles over the study period. * To assess if DG1 lens will slow the progression of myopia through an ad... Read More
Gender:
ALL
Ages:
Between 7 years and 10 years
Trial Updated:
02/07/2025
Locations: Virginia Pediatric Eye Center, Virginia Beach, Virginia
Conditions: Myopia
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: USOR - Virginia Oncology Associates - Virginia Beach, Virginia Beach, Virginia
Conditions: Myelofibrosis
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Recruiting
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with IR-NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Urology of Virginia (UVA) - Virginia Beach (Devine-Tidewater Urology), Virginia Beach, Virginia
Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Recruiting
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
01/21/2025
Locations: Sentara Neuroscience Institute, Virginia Beach, Virginia
Conditions: Relapsing-Remitting Multiple Sclerosis